PPP2R1A mutations portend improved survival after cancer immunotherapy



Summary

Mutations in the PPP2R1A gene, encoding a scaffolding subunit of the PP2A phosphatase complex, are linked to better survival outcomes in cancer patients treated with immunotherapy. Analysis of pan-cancer datasets revealed that PPP2R1A-mutated tumors exhibit increased immune cell infiltration and a more favorable tumor microenvironment. Specifically, these mutations enhance the activity of the STING pathway, a key component of the innate immune response. This heightened immune activation leads to improved responses to immunotherapy, suggesting that PPP2R1A mutation status could serve as a predictive biomarker for immunotherapy effectiveness.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!